KALA BIO, Inc. (NASDAQ:KALA) Short Interest Update

KALA BIO, Inc. (NASDAQ:KALA) saw a significant decline in short interest during the month of July. As of July 15th, there was short interest totalling 65,800 shares, a decline of 77.7% from the June 30th total of 295,200 shares. Based on an average daily trading volume, of 231,600 shares, the short-interest ratio is currently 0.3 days. Currently, 3.0% of the company’s stock are sold short.

KALA BIO Stock Performance

KALA stock traded down $0.34 on Friday, hitting $6.91. The company had a trading volume of 32,804 shares, compared to its average volume of 119,553. The stock’s 50-day simple moving average is $6.53 and its 200 day simple moving average is $7.02. KALA BIO has a 12-month low of $4.21 and a 12-month high of $15.94. The company has a current ratio of 4.22, a quick ratio of 4.22 and a debt-to-equity ratio of 4.92. The stock has a market cap of $19.47 million, a price-to-earnings ratio of -0.46 and a beta of -2.04.

KALA BIO (NASDAQ:KALA) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($4.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.89) by ($1.31). As a group, equities research analysts expect that KALA BIO will post -14.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on KALA. HC Wainwright cut their price target on shares of KALA BIO from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, May 17th. Oppenheimer reiterated an “outperform” rating and set a $15.00 price target on shares of KALA BIO in a research report on Monday, April 1st.

Insider Activity at KALA BIO

In other KALA BIO news, CEO Mark T. Iwicki sold 15,168 shares of the business’s stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $4.75, for a total value of $72,048.00. Following the transaction, the chief executive officer now owns 263,755 shares of the company’s stock, valued at $1,252,836.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CEO Mark T. Iwicki sold 7,392 shares of the business’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $6.09, for a total transaction of $45,017.28. Following the completion of the transaction, the chief executive officer now directly owns 278,923 shares in the company, valued at $1,698,641.07. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Mark T. Iwicki sold 15,168 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $4.75, for a total transaction of $72,048.00. Following the completion of the transaction, the chief executive officer now directly owns 263,755 shares of the company’s stock, valued at approximately $1,252,836.25. The disclosure for this sale can be found here. Insiders have sold a total of 35,255 shares of company stock valued at $182,564 over the last 90 days. Insiders own 13.40% of the company’s stock.

Institutional Trading of KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. Tower Research Capital LLC TRC bought a new stake in shares of KALA BIO, Inc. (NASDAQ:KALA) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 4,357 shares of the company’s stock, valued at approximately $30,000. Tower Research Capital LLC TRC owned approximately 0.16% of KALA BIO at the end of the most recent reporting period. 24.61% of the stock is currently owned by institutional investors and hedge funds.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.